CN1178665C - 唑系化合物的水溶性前药 - Google Patents

唑系化合物的水溶性前药 Download PDF

Info

Publication number
CN1178665C
CN1178665C CNB018038581A CN01803858A CN1178665C CN 1178665 C CN1178665 C CN 1178665C CN B018038581 A CNB018038581 A CN B018038581A CN 01803858 A CN01803858 A CN 01803858A CN 1178665 C CN1178665 C CN 1178665C
Authority
CN
China
Prior art keywords
compound
hydroxyl
chemical compound
phenyl
tert
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB018038581A
Other languages
English (en)
Chinese (zh)
Other versions
CN1395485A (zh
Inventor
Y�����ڴ���
Y·乌达
J·D·马逖斯克拉
J·格里克
T·W·哈狄玛
陈中冰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
R& D Management Co Ltd
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN1395485A publication Critical patent/CN1395485A/zh
Application granted granted Critical
Publication of CN1178665C publication Critical patent/CN1178665C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having three nitrogen atoms as the only ring hetero atoms
    • C07F9/6518—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polymerization Catalysts (AREA)
CNB018038581A 2000-01-20 2001-01-16 唑系化合物的水溶性前药 Expired - Lifetime CN1178665C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17716900P 2000-01-20 2000-01-20
US60/177,169 2000-01-20
US24996900P 2000-11-20 2000-11-20
US60/249,969 2000-11-20

Publications (2)

Publication Number Publication Date
CN1395485A CN1395485A (zh) 2003-02-05
CN1178665C true CN1178665C (zh) 2004-12-08

Family

ID=26873001

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018038581A Expired - Lifetime CN1178665C (zh) 2000-01-20 2001-01-16 唑系化合物的水溶性前药

Country Status (22)

Country Link
US (1) US6362172B2 (enExample)
EP (1) EP1284737B1 (enExample)
JP (1) JP3766804B2 (enExample)
KR (1) KR100748299B1 (enExample)
CN (1) CN1178665C (enExample)
AT (1) ATE300946T1 (enExample)
AU (1) AU782177C (enExample)
BR (1) BR0107618A (enExample)
CA (1) CA2397734C (enExample)
CZ (1) CZ20022822A3 (enExample)
DE (1) DE60112433T2 (enExample)
DK (1) DK1284737T5 (enExample)
ES (1) ES2247131T3 (enExample)
HU (1) HU229226B1 (enExample)
IL (2) IL150798A0 (enExample)
MX (1) MXPA02007120A (enExample)
NO (1) NO330352B1 (enExample)
NZ (1) NZ519354A (enExample)
PL (1) PL206024B1 (enExample)
PT (1) PT1284737E (enExample)
RU (1) RU2266909C2 (enExample)
WO (1) WO2001052852A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104926870A (zh) * 2014-03-21 2015-09-23 合肥久诺医药科技有限公司 一种福司氟康唑的精制方法

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6448401B1 (en) * 2000-11-20 2002-09-10 Bristol-Myers Squibb Company Process for water soluble azole compounds
HUP0303249A3 (en) 2001-02-22 2007-03-28 Sankyo Co Water-soluble triazole fungicide compounds and pharmaceutical compositions containing them
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
IL166241A0 (en) 2002-07-29 2006-01-15 Rigel Pharmaceuticals Inc Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
ES2421139T3 (es) 2003-07-30 2013-08-29 Rigel Pharmaceuticals, Inc. Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US7449458B2 (en) 2005-01-19 2008-11-11 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
JO2691B1 (en) * 2005-05-03 2013-03-03 ايساي آر آند دي مانجمنت كو.، ليمتد Monolysine salts for azole compounds
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1964843B1 (en) * 2005-12-20 2013-08-28 Eisai R&D Management Co., Ltd. Process for production of water-soluble azole prodrug
WO2007092580A2 (en) * 2006-02-08 2007-08-16 Phibro-Tech Inc. Biocidal azole emulsion concentrates having high active ingredient content
KR101250632B1 (ko) 2006-02-22 2013-04-03 에자이 알앤드디 매니지먼트 가부시키가이샤 안정화 의약 조성물
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
BRPI0711558A2 (pt) 2006-05-04 2011-11-08 Boeringer Ingelheim Internat Gmbh polimorfos
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
JP5757864B2 (ja) * 2008-05-20 2015-08-05 ニューロジェシックス， インコーポレイテッド 水溶性アセトアミノフェン類似体
AU2009249069A1 (en) * 2008-05-20 2009-11-26 Neurogesx, Inc. Carbonate prodrugs and methods of using the same
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
AU2009290911A1 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EP2382216A1 (en) 2008-12-23 2011-11-02 Boehringer Ingelheim International GmbH Salt forms of organic compound
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
EA034869B1 (ru) 2009-11-27 2020-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
MX341025B (es) 2010-05-05 2016-08-04 Boehringer Ingelheim Int Gmbh * Terapia de combinacion.
PH12012502524A1 (en) 2010-06-24 2014-02-10 Boehringer Ingelheim Int Diabetes therapy
WO2012060448A1 (ja) 2010-11-05 2012-05-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗真菌剤としての併用医薬組成物
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
CN103402543B (zh) * 2010-12-16 2015-09-16 德克萨斯州立大学董事会 用于胃肠外施用的吡咯药物制剂及其制备方法和治疗对吡咯化合物敏感的疾病的使用方法
EP2723452A2 (en) 2011-06-22 2014-04-30 Vyome Biosciences Pvt Ltd Conjugate-based antifungal and antibacterial prodrugs
EP3517539B1 (en) 2011-07-15 2022-12-14 Boehringer Ingelheim International GmbH Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
US8426450B1 (en) * 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
IN2014DN06792A (enExample) * 2012-01-20 2015-05-22 Viamet Pharmaceuticals Inc
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9981040B2 (en) * 2012-04-20 2018-05-29 Eisai R&D Management Co., Ltd. Capsule formulation
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2014195872A1 (en) 2013-06-04 2014-12-11 Vyome Biosciences Pvt. Ltd. Coated particles and compositions comprising same
CN113559105B (zh) 2014-01-29 2026-06-23 维奥姆治疗有限公司 抗性痤疮的治疗
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
EP3328819B1 (en) * 2015-07-28 2020-04-01 Beta Cat Pharmaceuticals, Inc. Anthracene-9, 10-dione dioxime compounds prodrugs and their uses
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合
CN107501255B (zh) * 2017-09-12 2019-08-23 成都施贝康生物医药科技有限公司 一种艾沙康唑衍生物及其用途
CN108676031A (zh) * 2018-05-29 2018-10-19 重庆威鹏药业有限公司 水溶性三唑类抗真菌膦酸化合物及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8819308D0 (en) * 1988-08-13 1988-09-14 Pfizer Ltd Triazole antifungal agents
GB9002375D0 (en) * 1990-02-02 1990-04-04 Pfizer Ltd Triazole antifungal agents
NO310238B1 (no) 1992-12-24 2001-06-11 Bristol Myers Squibb Co Kjemiske forbindelser og farmasöytisk preparat samt anvendelse av slike preparater
CA2129288C (en) 1993-08-17 2000-05-16 Jerzy Golik Phosphonooxymethyl esters of taxane derivatives
DK0736030T3 (da) 1993-12-21 2001-10-29 Schering Corp Fungicide tetrahydrofuraner
US5714490A (en) * 1993-12-21 1998-02-03 Schering Corporation Tetrahydrofuran antifungals
SG48386A1 (en) 1994-01-24 1998-04-17 Janssen Pharmaceutica Nv Watersoluble azole antifungals
NZ270418A (en) 1994-02-07 1997-09-22 Eisai Co Ltd Polycyclic triazole & imidazole derivatives, antifungal compositions
ES2199291T3 (es) 1995-06-02 2004-02-16 Schering Corporation Antifungicos de tetrahidrofurano.
TW354293B (en) * 1995-06-06 1999-03-11 Bristol Myers Squibb Co Prodrugs of paclitaxel derivatives
GB9602080D0 (en) 1996-02-02 1996-04-03 Pfizer Ltd Pharmaceutical compounds
EP0829478A3 (en) 1996-09-09 1998-03-25 F. Hoffmann-La Roche Ag N-Benzylimidazolium and N-benzyltriazolium derivatives, their preparation and their use as antifungal and antimycotic agents
DK1056754T3 (da) 1998-01-29 2004-02-16 Bristol Myers Squibb Co Phosphatderivater af diaryl-1,3,4-oxadiazolon
US5883097A (en) 1998-04-16 1999-03-16 Schering Corporation Soluble azole antifungal salt
US6204257B1 (en) 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
WO2000030655A1 (en) * 1998-11-20 2000-06-02 Bristol-Myers Squibb Company Water soluble prodrugs of azole compounds
US6448401B1 (en) * 2000-11-20 2002-09-10 Bristol-Myers Squibb Company Process for water soluble azole compounds

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104926870A (zh) * 2014-03-21 2015-09-23 合肥久诺医药科技有限公司 一种福司氟康唑的精制方法
CN104926870B (zh) * 2014-03-21 2017-02-08 合肥久诺医药科技有限公司 一种福司氟康唑的精制方法

Also Published As

Publication number Publication date
PL206024B1 (pl) 2010-06-30
AU782177B2 (en) 2005-07-07
EP1284737A4 (en) 2003-03-19
NO20023468D0 (no) 2002-07-19
CA2397734A1 (en) 2001-07-26
AU2948501A (en) 2001-07-31
ES2247131T3 (es) 2006-03-01
CA2397734C (en) 2010-08-17
AU782177C (en) 2007-10-18
KR100748299B1 (ko) 2007-08-09
RU2266909C2 (ru) 2005-12-27
HUP0204405A2 (en) 2003-05-28
CZ20022822A3 (cs) 2003-02-12
CN1395485A (zh) 2003-02-05
PT1284737E (pt) 2005-11-30
NZ519354A (en) 2004-05-28
EP1284737B1 (en) 2005-08-03
US6362172B2 (en) 2002-03-26
EP1284737A1 (en) 2003-02-26
IL150798A (en) 2006-08-01
HU229226B1 (en) 2013-09-30
KR20020070492A (ko) 2002-09-09
PL356164A1 (en) 2004-06-14
DK1284737T3 (da) 2005-11-28
JP3766804B2 (ja) 2006-04-19
WO2001052852A1 (en) 2001-07-26
DE60112433D1 (de) 2005-09-08
DK1284737T5 (da) 2007-09-24
ATE300946T1 (de) 2005-08-15
DE60112433T2 (de) 2006-05-18
JP2003520235A (ja) 2003-07-02
US20010041691A1 (en) 2001-11-15
NO20023468L (no) 2002-07-29
BR0107618A (pt) 2002-11-12
IL150798A0 (en) 2003-02-12
HUP0204405A3 (en) 2005-02-28
NO330352B1 (no) 2011-04-04
MXPA02007120A (es) 2003-01-28

Similar Documents

Publication Publication Date Title
CN1395485A (zh) 唑系化合物的水溶性前药
CN1085213C (zh) 用于治疗的三唑衍生物
CN1066713C (zh) 茋衍生物和含有它们的药物组合物
US9802901B2 (en) Antibacterial 2H-indazole derivatives
CN1279033C (zh) 水溶性唑化合物的改善方法
US6486159B2 (en) Water soluble prodrugs of azole compounds
AU2002213317A1 (en) Improved process for water soluble azole compounds
CN101213193B (zh) 唑类化合物的单赖氨酸盐
CN1030658C (zh) 十八烷基-[2-(n-甲基哌啶子基)-乙基]-磷酸酯的制备方法
US20170217996A1 (en) Large-scale diastereoselective syntheses of cycloheptadienylsulfones and stereotetrads
CN1407980A (zh) 杂环衍生物
CN1291610A (zh) 具有抗真菌活性的三唑衍生物
CN1114835A (zh) 膦酸二酯衍生物
CN117377660A (zh) 用于苯并氧氮杂䓬恶唑烷酮化合物的制备的方法
HK1018217B (zh) 用於治疗的三唑衍生物
WO2000071498A1 (en) Improved process for azole antifungal intermediate

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: EISAI CO., LTD.

Free format text: FORMER OWNER: BRISTOL-MYERS SQUIBB CO.

Effective date: 20050916

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20050916

Address after: Tokyo, Japan

Patentee after: Eisai Co.,Ltd.

Address before: American New Jersey

Patentee before: Bristol-Myers Squibb Co.

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT PATENT RIGHT TRANSFER; FROM: EISAI CO., LTD.; TO: WEI CAI + D MANAGEMENT CO., LTD.

Effective date: 20070709

TR01 Transfer of patent right

Effective date of registration: 20070709

Address after: Tokyo, Japan

Patentee after: R& D Management Co., Ltd.

Address before: Tokyo, Japan

Patentee before: Eisai Co.,Ltd.

CX01 Expiry of patent term

Granted publication date: 20041208

CX01 Expiry of patent term